Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder (Q38460499)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder |
scientific article |
Statements
1 reference
Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder (English)
1 reference
1 reference
Steven A Kaplan
1 reference
David Mitcheson
1 reference
Jiri Klecka
1 reference
Jana Cummings
1 reference
Ted Drogendijk
1 reference
Caroline Dorrepaal
1 reference
Nancy Martin
1 reference
6 November 2012
1 reference
1 reference
63
1 reference
2
1 reference
296-305
1 reference
Identifiers
1 reference
1 reference